# How two retatrutide trials counted breathing interruptions during sleep

- Article ID: research-309
- Product: RETA GLP-3 (reta-glp-3-689, reta-glp-3-690, reta-glp-3-705, reta-glp-3-706)
- Canonical page: https://heritagebiolabs.com/research-library/articles/309-how-two-retatrutide-trials-counted-breathing-interruptions-during-sleep
- Product collection: https://heritagebiolabs.com/research-library/products/reta-glp-3
- Product page: https://heritagebiolabs.com/product/reta-glp-3-689
- Product page: https://heritagebiolabs.com/product/reta-glp-3-690
- Product page: https://heritagebiolabs.com/product/reta-glp-3-705
- Product page: https://heritagebiolabs.com/product/reta-glp-3-706
- Reading focus: Mechanisms & biology (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2025, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids held together by peptide bonds. Researchers can modify a chain so it activates several receptors involved in metabolism. Retatrutide is an investigational peptide that activates the GIP, GLP-1 and glucagon receptors. “RETA GLP-3” is a catalog label. Its number does not name a receptor target. A 2026 report examined retatrutide in adults with moderate to severe obstructive sleep apnea. [1, 2]

The study reported two randomized, double-blind comparisons within the larger TRIUMPH program. One included people without type 2 diabetes and the other included people with it. All participants in these sleep apnea comparisons had a body mass index of at least 27 and moderate to severe obstructive sleep apnea. The researchers assigned people to retatrutide or placebo and assessed breathing at 80 weeks. There were 243 randomized participants in the first comparison and 448 in the second. [1]

The main measure was the apnea-hypopnea index, the average number of times per hour of sleep that breathing stopped or decreased enough to meet the study definition. In the trial without diabetes, average reductions in the two principal active groups were about 34 and 32 events per hour, compared with about 10 with placebo. In the trial with type 2 diabetes, the corresponding reductions were about 25 events per hour in both principal active groups and 10 with placebo. These values come from the authors’ main statistical analysis. [1]

The analysis applied different assumptions depending on events that occurred after people were assigned to treatment. For specified events suggesting treatment failure, it estimated results under a hypothetical scenario. It used a treatment-policy approach for other events. The authors also reported results based on intention to treat. Seeing both sets of results helps readers understand what the researchers assumed when estimating changes in participants’ breathing. [1]

The comparisons tell us about the frequency of interrupted breathing in a particular population over the tested period. Those counts do not describe every feature of sleep, oxygen levels or daytime function. The sleep apnea analyses were also nested in the larger TRIUMPH program, so their data overlap with reports from the parent trials. They should not be counted as independent replications of the parent trial results. The intervention remains investigational. The result in these participants is evidence about the tested formulation under trial conditions, while any regulatory indication would be a separate decision. [1, 2, 3]

## Sources

1. R. R. Grunstein et al. Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea. The New England Journal of Medicine (publication 2026-10-21). <https://www.nejm.org/doi/full/10.1056/NEJMoa2611477>
2. Ania M. Jastreboff et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. The New England Journal of Medicine (publication 2026-09-29). <https://pubmed.ncbi.nlm.nih.gov/42814954/>
3. U.S. Food and Drug Administration. Darmerica, LLC - 716152 - 12/08/2025. FDA warning letter (publication 2025-12-08). <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/darmerica-llc-716152-12082025>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 062 - PT-141 and RETA GLP-3.docx; article 309; content SHA-256 06d286c678825cceeacebbe389316506d7a9ef96bd3291d922db58f25eedbd83.
